Eldecalcitol for the treatment of osteoporosis

Yuko Noguchi, Hisaya Kawate, Masatoshi Nomura, Ryoichi Takayanagi

研究成果: ジャーナルへの寄稿評論記事

8 引用 (Scopus)

抄録

Eldecalcitol (1α, 25-dihydroxy-2β-[3-hydroxypropyloxy] vitamin D3; ED-71) is a new analog of the active form of vitamin D. Eldecalcitol has recently been approved for the treatment of osteoporosis in Japan. In addition to regulation of calcium metabolism carried out by conventional vitamin D analogs, eldecalcitol possesses a strong inhibitory effect on bone resorption and causes a significant increase in bone mineral density. A Phase III clinical trial on osteoporosis showed that eldecalcitol reduced the incidence of new vertebral fractures over 3 years by 26% compared with alfacalcidol. Although the overall risk of nonvertebral fractures was not reduced by eldecalcitol, the risk of wrist fracture was decreased significantly in the eldecalcitol group (71%) compared with the alfacalcidol group. The serum level of 25-hydroxyvitamin D (25[OH]D) was normalized by supplementation of native vitamin D in this trial, so the desirable effects on bone by eldecalcitol were considered to be derived from its distinctive pharmacological action. Increased blood calcium was observed in 21% of patients treated with eldecalcitol, and hypercalcemia (.11.5 mg/dL) occurred in 0.4% of eldecalcitol recipients, so serum calcium concentration should be monitored after starting eldecalcitol treatment. Eldecalcitol has dual effects on the metabolism of bone and calcium and is useful for the treatment of osteoporosis, especially for elderly patients (who frequently suffer from vitamin D deficiency). This article reviews the clinical efficacy and safety of eldecalcitol in the treatment of osteoporosis.

元の言語英語
ページ(範囲)1313-1321
ページ数9
ジャーナルClinical interventions in aging
8
DOI
出版物ステータス出版済み - 9 26 2013

Fingerprint

Osteoporosis
Therapeutics
Vitamin D
Calcium
eldecalcitol
Bone and Bones
Phase III Clinical Trials
Vitamin D Deficiency
Cholecalciferol
Hypercalcemia
Bone Resorption
Wrist
Serum
Bone Density
Japan
Pharmacology
Safety
Incidence

All Science Journal Classification (ASJC) codes

  • Geriatrics and Gerontology

これを引用

Noguchi, Y., Kawate, H., Nomura, M., & Takayanagi, R. (2013). Eldecalcitol for the treatment of osteoporosis. Clinical interventions in aging, 8, 1313-1321. https://doi.org/10.2147/CIA.S49825

Eldecalcitol for the treatment of osteoporosis. / Noguchi, Yuko; Kawate, Hisaya; Nomura, Masatoshi; Takayanagi, Ryoichi.

:: Clinical interventions in aging, 巻 8, 26.09.2013, p. 1313-1321.

研究成果: ジャーナルへの寄稿評論記事

Noguchi, Y, Kawate, H, Nomura, M & Takayanagi, R 2013, 'Eldecalcitol for the treatment of osteoporosis', Clinical interventions in aging, 巻. 8, pp. 1313-1321. https://doi.org/10.2147/CIA.S49825
Noguchi, Yuko ; Kawate, Hisaya ; Nomura, Masatoshi ; Takayanagi, Ryoichi. / Eldecalcitol for the treatment of osteoporosis. :: Clinical interventions in aging. 2013 ; 巻 8. pp. 1313-1321.
@article{7afd58026d124a51b03a68398ac5fb79,
title = "Eldecalcitol for the treatment of osteoporosis",
abstract = "Eldecalcitol (1α, 25-dihydroxy-2β-[3-hydroxypropyloxy] vitamin D3; ED-71) is a new analog of the active form of vitamin D. Eldecalcitol has recently been approved for the treatment of osteoporosis in Japan. In addition to regulation of calcium metabolism carried out by conventional vitamin D analogs, eldecalcitol possesses a strong inhibitory effect on bone resorption and causes a significant increase in bone mineral density. A Phase III clinical trial on osteoporosis showed that eldecalcitol reduced the incidence of new vertebral fractures over 3 years by 26{\%} compared with alfacalcidol. Although the overall risk of nonvertebral fractures was not reduced by eldecalcitol, the risk of wrist fracture was decreased significantly in the eldecalcitol group (71{\%}) compared with the alfacalcidol group. The serum level of 25-hydroxyvitamin D (25[OH]D) was normalized by supplementation of native vitamin D in this trial, so the desirable effects on bone by eldecalcitol were considered to be derived from its distinctive pharmacological action. Increased blood calcium was observed in 21{\%} of patients treated with eldecalcitol, and hypercalcemia (.11.5 mg/dL) occurred in 0.4{\%} of eldecalcitol recipients, so serum calcium concentration should be monitored after starting eldecalcitol treatment. Eldecalcitol has dual effects on the metabolism of bone and calcium and is useful for the treatment of osteoporosis, especially for elderly patients (who frequently suffer from vitamin D deficiency). This article reviews the clinical efficacy and safety of eldecalcitol in the treatment of osteoporosis.",
author = "Yuko Noguchi and Hisaya Kawate and Masatoshi Nomura and Ryoichi Takayanagi",
year = "2013",
month = "9",
day = "26",
doi = "10.2147/CIA.S49825",
language = "English",
volume = "8",
pages = "1313--1321",
journal = "Clinical Interventions in Aging",
issn = "1176-9092",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Eldecalcitol for the treatment of osteoporosis

AU - Noguchi, Yuko

AU - Kawate, Hisaya

AU - Nomura, Masatoshi

AU - Takayanagi, Ryoichi

PY - 2013/9/26

Y1 - 2013/9/26

N2 - Eldecalcitol (1α, 25-dihydroxy-2β-[3-hydroxypropyloxy] vitamin D3; ED-71) is a new analog of the active form of vitamin D. Eldecalcitol has recently been approved for the treatment of osteoporosis in Japan. In addition to regulation of calcium metabolism carried out by conventional vitamin D analogs, eldecalcitol possesses a strong inhibitory effect on bone resorption and causes a significant increase in bone mineral density. A Phase III clinical trial on osteoporosis showed that eldecalcitol reduced the incidence of new vertebral fractures over 3 years by 26% compared with alfacalcidol. Although the overall risk of nonvertebral fractures was not reduced by eldecalcitol, the risk of wrist fracture was decreased significantly in the eldecalcitol group (71%) compared with the alfacalcidol group. The serum level of 25-hydroxyvitamin D (25[OH]D) was normalized by supplementation of native vitamin D in this trial, so the desirable effects on bone by eldecalcitol were considered to be derived from its distinctive pharmacological action. Increased blood calcium was observed in 21% of patients treated with eldecalcitol, and hypercalcemia (.11.5 mg/dL) occurred in 0.4% of eldecalcitol recipients, so serum calcium concentration should be monitored after starting eldecalcitol treatment. Eldecalcitol has dual effects on the metabolism of bone and calcium and is useful for the treatment of osteoporosis, especially for elderly patients (who frequently suffer from vitamin D deficiency). This article reviews the clinical efficacy and safety of eldecalcitol in the treatment of osteoporosis.

AB - Eldecalcitol (1α, 25-dihydroxy-2β-[3-hydroxypropyloxy] vitamin D3; ED-71) is a new analog of the active form of vitamin D. Eldecalcitol has recently been approved for the treatment of osteoporosis in Japan. In addition to regulation of calcium metabolism carried out by conventional vitamin D analogs, eldecalcitol possesses a strong inhibitory effect on bone resorption and causes a significant increase in bone mineral density. A Phase III clinical trial on osteoporosis showed that eldecalcitol reduced the incidence of new vertebral fractures over 3 years by 26% compared with alfacalcidol. Although the overall risk of nonvertebral fractures was not reduced by eldecalcitol, the risk of wrist fracture was decreased significantly in the eldecalcitol group (71%) compared with the alfacalcidol group. The serum level of 25-hydroxyvitamin D (25[OH]D) was normalized by supplementation of native vitamin D in this trial, so the desirable effects on bone by eldecalcitol were considered to be derived from its distinctive pharmacological action. Increased blood calcium was observed in 21% of patients treated with eldecalcitol, and hypercalcemia (.11.5 mg/dL) occurred in 0.4% of eldecalcitol recipients, so serum calcium concentration should be monitored after starting eldecalcitol treatment. Eldecalcitol has dual effects on the metabolism of bone and calcium and is useful for the treatment of osteoporosis, especially for elderly patients (who frequently suffer from vitamin D deficiency). This article reviews the clinical efficacy and safety of eldecalcitol in the treatment of osteoporosis.

UR - http://www.scopus.com/inward/record.url?scp=84884687008&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884687008&partnerID=8YFLogxK

U2 - 10.2147/CIA.S49825

DO - 10.2147/CIA.S49825

M3 - Review article

C2 - 24101867

AN - SCOPUS:84884687008

VL - 8

SP - 1313

EP - 1321

JO - Clinical Interventions in Aging

JF - Clinical Interventions in Aging

SN - 1176-9092

ER -